We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

11 hedge funds and large institutions have $419K invested in Galmed Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.67% more ownership

Funds ownership: 0.05% → 0.71% (+0.67%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

45% less funds holding

Funds holding: 20 → 11 (-9)

52% less capital invested

Capital invested by funds: $878K → $419K (-$459K)

82% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 11

Holders
11
Holders Change
-9
Holders Change %
-45%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$115K
2
Millennium Management
Millennium Management
New York
+$27.6K
3
TRCT
Tower Research Capital (TRC)
New York
+$216

Top Sellers

Rank Fund Capital Flow
1
RJA
Raymond James & Associates
Florida
-$58.9K
2
Citadel Advisors
Citadel Advisors
Florida
-$17.4K
3
VF
Virtu Financial
New York
-$13K
4
WWM
Western Wealth Management
Colorado
-$12.6K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$261K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$74.5K +$115K +2,133 New
Millennium Management
3
Millennium Management
New York
$43.4K +$27.6K +511 +70%
Morgan Stanley
4
Morgan Stanley
New York
$37.4K -$5.03K -93 -8%
TFGT
5
TS Financial Group (TSFG)
Illinois
$1K – – –
Wells Fargo
6
Wells Fargo
California
$610 – – –
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Quebec, Canada
$499 – – –
TRCT
8
Tower Research Capital (TRC)
New York
$152 +$216 +4 New
BCM
9
Bourgeon Capital Management
Connecticut
$102 – – –
AF
10
Allworth Financial
California
$51 – – –
EWP
11
Elevation Wealth Partners
California
$21 – – –
UBS Group
12
UBS Group
Switzerland
$3 -$1.3K -24 Closed
RJA
13
Raymond James & Associates
Florida
– -$58.9K -767 Closed
Citadel Advisors
14
Citadel Advisors
Florida
– -$17.4K -227 Closed
VF
15
Virtu Financial
New York
– -$13K -176 Closed
WWM
16
Western Wealth Management
Colorado
– -$12.6K -164 Closed
Cambridge Investment Research Advisors
17
Cambridge Investment Research Advisors
Iowa
– -$12K -158 Closed
RJFSA
18
Raymond James Financial Services Advisors
Florida
– -$11.9K -155 Closed
Geode Capital Management
19
Geode Capital Management
Massachusetts
– -$11.6K -151 Closed
BAM
20
Belpointe Asset Management
Nevada
– -$5.99K -78 Closed
BNP Paribas Financial Markets
21
BNP Paribas Financial Markets
France
– -$5.85K -76 Closed
Jane Street
22
Jane Street
New York
– -$5.63K -73 Closed
Northwestern Mutual Wealth Management
23
Northwestern Mutual Wealth Management
Wisconsin
– -$4 – –

GLMD Hedge Fund Activity: Q2 2023 in Review

11 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2023, worth a combined $419K — down 52% from $878K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of GLMD and 2 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $115K. The largest seller was Raymond James & Associates, exiting entirely with an estimated $58.9K sold.

  • 11 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2023, down from 20 in Q1 2023.
  • Funds reported $419K of Galmed Pharmaceuticals stock for Q2 2023, down 52% quarter-over-quarter.
  • 2 funds opened new Galmed Pharmaceuticals positions in Q2 2023 and 11 closed out, a net change of -9 holders.
  • The largest Galmed Pharmaceuticals buyer in Q2 2023 was Susquehanna International Group, an estimated $115K added.
  • The largest Galmed Pharmaceuticals seller in Q2 2023 was Raymond James & Associates, an estimated $58.9K sold.

Based on aggregated 13F filings for Q2 2023.